TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00421967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine, Ketorolac, adrenaline
Description: Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Ketorolac
Description: Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
Study: NCT04020016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER
Description: Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine ER -
Description: Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days.
Study: NCT04559841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bone substitute; NanoBone®
Description: surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone substitute; NanoBone®
Description: surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
Study: NCT02111109

Intervention type: DEVICE
Intervention: Side Stream Dark Field Microscopy
Study: NCT01652404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment
Description: The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The antibiotics duration will be determined by treating physician.
Study: NCT01448304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study: NCT02019836

Intervention type: OTHER
Intervention: Determining maternal and neonatal vitamin D levels
Study: NCT02886364

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Safe Childbirth Checklist
Description: The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
Study: NCT01046669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TORAYMYXIN PMX-20R (PMX cartridge)
Description: TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard medical care for septic shock
Description: Standard medical care for septic shock

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care for septic shock
Description: Standard medical care for septic shock
Study: NCT02239042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: LLLT
Description: The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
Study: NCT02522052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue mussel diet
Description: 5 meals a week containing blue mussels

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat/Control diet
Description: 5 meals a week containing meat
Study: NCT00674973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
Study: NCT04237012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Intracanalicular Insert
Description: all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Over the counter Artificial tears
Description: over the counter artificial tears PRN at patient discretion
Study: NCT04285099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of dual system in frequency A
Description: The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of dual system in frequency B
Description: The investigators set two values of frequency (130, 60Hz) in IPG and allow the patients to change the frequencies freely using the patient controller. Technician randomly sets 130 Hz, 60HZ to A or B.
Study: NCT02804529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veress needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veress needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veress needle
Study: NCT01155219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geltim LP 1 mg/g
Description: one drop in the conjunctival sac of each eye in the morning (84 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan
Description: one drop in the conjunctival sac of each eye in the morning (84 days).
Study: NCT01130428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvent 1000 Vibration Platform
Description: As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes.
Study: NCT04986254

Intervention type: OTHER
Intervention: Urine sampling
Description: The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.

Intervention type: DRUG
Intervention: Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Description: Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.

Intervention type: DRUG
Intervention: Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Description: Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
Study: NCT02915601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Study: NCT01929993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWETZ
Description: Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
Study: NCT02915601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01929993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ cone
Description: LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
Study: NCT04986254

Intervention type: DRUG
Intervention: Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Description: Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.

Intervention type: DRUG
Intervention: Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam
Description: Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
Study: NCT01632449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product
Description: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product
Description: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference product
Description: Dimethyl Fumarate (BG00012)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference product
Description: Dimethyl Fumarate (BG00012)
Study: NCT04274829

Intervention type: PROCEDURE
Intervention: Thyroidecomt and lymphectomy
Description: Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
Study: NCT01680367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound care management
Description: Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound care management
Description: Receive native collagen wound dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03680261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
Study: NCT04012216

Intervention type: DEVICE
Intervention: Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)
Description: A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.

Intervention type: DEVICE
Intervention: Gold standard: polysomnography
Description: Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
Study: NCT04955015

Intervention type: PROCEDURE
Intervention: carotid endarterectomy
Description: patients with carotid atherosclerosis refering to CEA
Study: NCT04580615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiacSense1 and capnograph Respiratory rate measurement
Description: Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
Study: NCT05798637

Intervention type: OTHER
Intervention: Standard of care
Description: No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)

Intervention type: OTHER
Intervention: Standard of care
Description: No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)

Intervention type: OTHER
Intervention: Standard of care
Description: No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)

Intervention type: OTHER
Intervention: Standard of care
Description: No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)

Intervention type: OTHER
Intervention: Standard of care
Description: No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
Study: NCT03121937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App
Description: The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication
Study: NCT04155840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study: NCT01335685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study: NCT03912896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taekwondo
Description: Children will participate in a 7-week taekwondo program.
Study: NCT02136108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPENtext
Description: Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPENnav
Description: Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
Study: NCT03012516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAP-treatment by physiotherapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary PAP-treatment at the health care center
Study: NCT02469376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-GP1
Description: Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
Study: NCT04378946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physical rehabilitation type training
Description: Multiple reaching tasks aiming at increasing voluntary elbow range of motion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive physical rehabilitation type training
Description: Multiple reaching tasks aiming at increasing voluntary elbow range of motion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic system for supporting and monitoring arm motion
Description: Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic system for supporting and monitoring arm motion
Description: Ergonomic double-joint horizontal manipulandum mounted on a rigid, movable arm (used to support UL movement during tasks).~An electromyogram (EMG) is used to monitor elbow extensor and flexor muscle activity.~A motion tracking device based on the Kinect II skeleton ( with Kalman filter to improve accuracy).~Simple Virtual Reality Reaching Game providing visual feedback with screen display of the subject's arm avatar and arm workspace for the VR training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph Activity Monitor
Description: Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph Activity Monitor
Description: Used during and outside training sessions, this device is worned on the affected wrist that records activity (movements metrics) as a measure of upper extremity as well as heart rate

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Description: Done once before treatment (PRE)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Done once before treatment (PRE)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Spasticity Measure (MSM)
Description: Used to identify the actual spatial threshold (ST) prior to every training session

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Montreal Spasticity Measure (MSM)
Description: Used to identify the actual spatial threshold (ST) prior to every training session
Study: NCT04473625

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Study: NCT04155840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV